Literature DB >> 32562218

Moyamoya disease and moyamoya syndrome in Ireland: patient demographics, mode of presentation and outcomes of EC-IC bypass surgery.

Ronan J Doherty1,2, John Caird3, Darach Crimmins3, Peter Kelly4, Sean Murphy4, Christopher McGuigan5, Niall Tubridy5, Mary D King3, Bryan Lynch3, David Webb6, Desmond O'Neill7, Dominick J H McCabe2,7,8,9, Peter Boers10, Mary O'Regan6, Joan Moroney1, David J Williams11, Simon Cronin12, Mohsen Javadpour13,14,15.   

Abstract

BACKGROUND: There are no previously published reports regarding the epidemiology and characteristics of moyamoya disease or syndrome in Ireland. AIMS: To examine patient demographics, mode of presentation and the outcomes of extracranial-intracranial bypass surgery in the treatment of moyamoya disease and syndrome in Ireland.
METHODS: All patients with moyamoya disease and syndrome referred to the National Neurosurgical Centre during January 2012-January 2019 were identified through a prospective database. Demographics, clinical presentation, radiological findings, surgical procedures, postoperative complications and any strokes during follow-up were recorded.
RESULTS: Twenty-one patients were identified. Sixteen underwent surgery. Median age at diagnosis was 19 years. Fifteen were female. Mode of presentation was ischaemic stroke in nine, haemodynamic TIAs in eight, haemorrhage in three and incidental in one. Sixteen patients had Moyamoya disease, whereas five patients had moyamoya syndrome. Surgery was performed on 19 hemispheres in 16 patients. The surgical procedures consisted of ten direct (STA-MCA) bypasses, five indirect bypasses and four multiple burr holes. Postoperative complications included ischaemic stroke in one patient and subdural haematoma in one patient. The median follow-up period in the surgical group was 52 months; there was one new stroke during this period. Two patients required further revascularisation following recurrent TIAs. One patient died during follow-up secondary to tumour progression associated with neurofibromatosis type 1.
CONCLUSIONS: Moyamoya is rare but occurs in Caucasians in Ireland. It most commonly presents with ischaemic symptoms. Surgical intervention in the form of direct and indirect bypass is an effective treatment in the majority of cases.

Entities:  

Keywords:  Extracranial-intracranial bypass; Incidence; Moyamoya disease; Moyamoya syndrome; Prevalence; Revascularisation

Mesh:

Year:  2020        PMID: 32562218     DOI: 10.1007/s11845-020-02280-w

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  29 in total

1.  The natural clinical course of hemodynamically stable adult moyamoya disease.

Authors:  Won-Sang Cho; Young Seob Chung; Jeong Eun Kim; Jin Pyeong Jeon; Young Je Son; Jae Seung Bang; Hyun-Seung Kang; Chul-Ho Sohn; Chang Wan Oh
Journal:  J Neurosurg       Date:  2015-01       Impact factor: 5.115

2.  A genome-wide association study identifies RNF213 as the first Moyamoya disease gene.

Authors:  Fumiaki Kamada; Yoko Aoki; Ayumi Narisawa; Yu Abe; Shoko Komatsuzaki; Atsuo Kikuchi; Junko Kanno; Tetsuya Niihori; Masao Ono; Naoto Ishii; Yuji Owada; Miki Fujimura; Yoichi Mashimo; Yoichi Suzuki; Akira Hata; Shigeru Tsuchiya; Teiji Tominaga; Yoichi Matsubara; Shigeo Kure
Journal:  J Hum Genet       Date:  2010-11-04       Impact factor: 3.172

Review 3.  Etiology and pathogenesis of Moyamoya Disease: An update on disease prevalence.

Authors:  Shuo Huang; Zhen-Ni Guo; Mingchao Shi; Yi Yang; Mingli Rao
Journal:  Int J Stroke       Date:  2017-01-01       Impact factor: 5.266

4.  Outcome in adult patients with hemorrhagic moyamoya disease after combined extracranial-intracranial bypass.

Authors:  Hanqiang Jiang; Wei Ni; Bin Xu; Yu Lei; Yanlong Tian; Feng Xu; Yuxiang Gu; Ying Mao
Journal:  J Neurosurg       Date:  2014-08-15       Impact factor: 5.115

5.  Characterization of Clinical and Radiological Features of Quasi-Moyamoya Disease among European Caucasians Including Surgical Treatment and Outcome.

Authors:  Güliz Acker; Susanne Goerdes; Peter Schmiedek; Marcus Czabanka; Peter Vajkoczy
Journal:  Cerebrovasc Dis       Date:  2016-08-27       Impact factor: 2.762

6.  Quantitative angiographic comparison with the OSIRIS program between the direct and indirect revascularization modalities in adult moyamoya disease.

Authors:  Jae Seung Bang; O-Ki Kwon; Jeong Eun Kim; Hyun-Seung Kang; Hyun Park; Sung Yun Cho; Chang Wan Oh
Journal:  Neurosurgery       Date:  2012-03       Impact factor: 4.654

7.  The natural history of moyamoya in a North American adult cohort.

Authors:  Bradley A Gross; Rose Du
Journal:  J Clin Neurosci       Date:  2012-11-10       Impact factor: 1.961

8.  Natural Course of Moyamoya Disease in Patients With Prior Hemorrhagic Stroke.

Authors:  Shuai Kang; Xingju Liu; Dong Zhang; Rong Wang; Yan Zhang; Qian Zhang; Wuyang Yang; Ji-Zong Zhao
Journal:  Stroke       Date:  2019-05       Impact factor: 7.914

Review 9.  Moyamoya disease and moyamoya syndrome.

Authors:  R Michael Scott; Edward R Smith
Journal:  N Engl J Med       Date:  2009-03-19       Impact factor: 91.245

10.  Novel epidemiological features of moyamoya disease.

Authors:  T Baba; K Houkin; S Kuroda
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-12-12       Impact factor: 10.154

View more
  3 in total

1.  Pediatric Moyamoya Disease and Syndrome in Italy: A Multicenter Cohort.

Authors:  Chiara Po'; Margherita Nosadini; Marialuisa Zedde; Rosario Pascarella; Giuseppe Mirone; Domenico Cicala; Anna Rosati; Alessandra Cosi; Irene Toldo; Raffaella Colombatti; Paola Martelli; Alessandro Iodice; Patrizia Accorsi; Lucio Giordano; Salvatore Savasta; Thomas Foiadelli; Giuseppina Sanfilippo; Elvis Lafe; Federico Zappoli Thyrion; Gabriele Polonara; Serena Campa; Federico Raviglione; Barbara Scelsa; Stefania Maria Bova; Filippo Greco; Duccio Maria Cordelli; Luigi Cirillo; Francesco Toni; Valentina Baro; Francesco Causin; Anna Chiara Frigo; Agnese Suppiej; Laura Sainati; Danila Azzolina; Manuela Agostini; Elisabetta Cesaroni; Luigi De Carlo; Gabriella Di Rosa; Giacomo Esposito; Luisa Grazian; Giovanna Morini; Francesco Nicita; Francesca Felicia Operto; Dario Pruna; Paola Ragazzi; Massimo Rollo; Alberto Spalice; Pasquale Striano; Aldo Skabar; Luigi Alberto Lanterna; Andrea Carai; Carlo Efisio Marras; Renzo Manara; Stefano Sartori
Journal:  Front Pediatr       Date:  2022-05-06       Impact factor: 3.418

2.  Incidence and prevalence of moyamoya disease in urban China: a nationwide retrospective cohort study.

Authors:  Yixin Sun; Guoyu Zhou; Jingnan Feng; Lu Chen; Guozhen Liu; Jinxi Wang; Qingliang Wang; Junyou Yu; Xiwang Yang; Zheng Yang; Pei Gao; Shengfeng Wang; Siyan Zhan
Journal:  Stroke Vasc Neurol       Date:  2021-05-03

Review 3.  Progression in Moyamoya Disease: Clinical Features, Neuroimaging Evaluation, and Treatment.

Authors:  Xin Zhang; Weiping Xiao; Qing Zhang; Ding Xia; Peng Gao; Jiabin Su; Heng Yang; Xinjie Gao; Wei Ni; Yu Lei; Yuxiang Gu
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.